Vijayakrishna K. Gadi, M.D. PHD
Medical Oncology Physician · Seattle, WA
Vijayakrishna K. Gadi, M.D. PHD is a medical oncology physician with a practice address in Seattle, Washington, and NPI 1053358671, issued on Jun 1, 2006. Check the license (Washington MD00041517, as entered in NPPES) on the Washington Medical Commission; the Medicare figures below come from public CMS files.
- Name
- Vijayakrishna K. Gadi
- Credential
- M.D. PHD
- Primary taxonomy
- Medical Oncology Physician 207RX0202X
- License numbers
- MD00041517 WA
036151951 IL
Self-reported in NPPES; status is on the state search - Practice location
- 825 Eastlake Ave E, Seattle, WA 98109
- Phone
- (206) 228-1000
- Enumerated
- Jun 1, 2006
- Record last updated
- Mar 5, 2025
- Medicaid ID
- 8385429 WA
- Medicare enrollment
- Enrolled (PECOS I20200618002922); accepts Medicare assignment
- Medical or professional school
- University Of Alabama School Of Medicine, 2000
- Telehealth
- Offers telehealth (CMS)
- Entity
- Type 1 · individual
Also registered at 825 Eastlake Ave E
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Farnoush Abar, M.D.Hematology & Oncology Physician1558560342
- Francis Achacoso, MBA, MSN, RN, NE-BCRegistered Nurse1215604061
- Bamidele Adebayo, MDNeurological Surgery Physician1255176194
- Oyebimpe Adesina, MDHematology & Oncology Physician1184934770
- Shirali AgarwalHematology & Oncology Physician1972093052
- Ali AlgiraigriSpecialist1467880260
Verify Vijayakrishna K. Gadi in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersWashington Medical Commission
Search for license MD00041517Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
86% fewer Medicare Part D claims than the average medical oncology physician in 2024
95 Medicare Part D claims for 27 beneficiaries, against an average of 703 among the 4,230 providers of this specialty who prescribed in Part D. Brand-name drugs were 25% of claims.
Most prescribed
- Votrient24 claims
- Tamoxifen Citrate16 claims
- Anastrozole12 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
The practice group's MIPS final score for 2023 (Medicare payment program): 87.1 of 100
The Merit-based Incentive Payment System score is reported for the practice group, not for one clinician alone. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.
Source: CMS Quality Payment Program, MIPS performance year 2023, group reporting; category weights for 2023 (qpp.cms.gov).
Industry payments in 2024: $106,018.91
98 payments; by number, the most common kind was food and beverage; the largest payer was Stemline Therapeutics Inc. The 3,343 providers of this specialty with any payment received $11,773.47 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Bills Medicare through one group practice
- The Board OF Trustees OF The University OF IllinoisChicago, IL
Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).
Medical Oncology Physician providers in Washington
There are 183 medical oncology physician records in Washington.
Other medical oncology physician records in Washington
- Amr Abd-Al-Ghaffar, MDWenatchee, WA1114904323
- Alireza Abdolmohammadi, MDTacoma, WA1871816207
- Manoj Agarwal, MD, MBABurien, WA1700891900
- Vyshak Alva Venur, M.DSeattle, WA1003171976
- Richard Ancheta, M.D.Everett, WA1184924870
- Willard Andes, MDLongview, WA1639215932
- Mirela Andrei, M.D.Spokane, WA1578875225
- Frederick AppelbaumSeattle, WA1356426183
- Navanshu Arora, MDRenton, WA1053366237
- Anthony Back, MDSeattle, WA1932285731
Common questions
What is Vijayakrishna K. Gadi, M.D. PHD's NPI number?
Vijayakrishna K. Gadi, M.D. PHD's National Provider Identifier (NPI) is 1053358671, issued on Jun 1, 2006. An NPI identifies a provider in billing; it is not a license.
Where is Vijayakrishna K. Gadi, M.D. PHD located?
The NPPES record lists a practice address at 825 Eastlake Ave E, Seattle, WA, 98109. Phone: (206) 228-1000. Providers update this record themselves, so call before visiting.
How can I verify Vijayakrishna K. Gadi, M.D. PHD's license?
NPPES lists Washington license number MD00041517, as entered by the provider. Search the Washington Medical Commission at https://wahelms.my.site.com/s/license-search. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Vijayakrishna K. Gadi, M.D. PHD prescribe under Medicare Part D?
In 2024, Vijayakrishna K. Gadi, M.D. PHD had 95 Medicare Part D claims for 27 beneficiaries; the average among medical oncology physician prescribers was 703. Part D covers Medicare prescriptions only.
What is Vijayakrishna K. Gadi, M.D. PHD's MIPS final score?
The 2023 MIPS final score is 87.1 of 100, reported for the practice group. The average among 454,083 clinicians with a measured score was 83.5.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.